Introduction {#sec1_1}
============

Peritransplant renal failure is an indicator of poor prognosis after liver transplantation \[[@B1], [@B2], [@B3], [@B4]\]. End-stage liver and kidney disease (ELKD) on hemodialysis is an indication for deceased donor simultaneous liver-kidney transplantation (LKT) \[[@B4], [@B5]\]. On the other hand, living donation of liver and a kidney is generally too challenging and invasive to be performed, and only a few cases of living donor simultaneous or sequential LKT for ELKD have been reported \[[@B6], [@B7], [@B8], [@B9], [@B10]\]. In living donor transplantation settings, the safer alternative approach is living donor liver transplantation (LDLT) and continuation of hemodialysis. However, LDLT for a patient on hemodialysis has never been reported, and thus the indications for LDLT in such patients are also unknown.

Here we present a case of successful LDLT for a patient with ELKD on hemodialysis. The indications for LDLT in patients on hemodialysis are presented and discussed.

Case Report {#sec1_2}
===========

The recipient was a 63-year-old Japanese male who had been suffering from hepatitis C cirrhosis since the age of 37 years. He had undergone endoscopic variceal ligation for esophageal varices at the age of 58 years. His liver function had gradually become decompensated and he had developed hepatic encephalopathy 5 months before admission. He had had cryptogenic chronic nephritis from the age of 19 years and started hemodialysis at the age of 60 years. He had no other complications such as diabetes, hypertension or hemodialysis-related complications. His height was 159 cm and his weight was 53 kg before hemodialysis and 51 kg after hemodialysis. His Child-Pugh score was 10 (grade C) with a total bilirubin level of 0.9 mg/dl, an albumin level of 3.4 g/dl and a prothrombin time of 68% (international ratio 1.25). He was seropositive for hepatitis C virus (HCV) antibodies but seronegative for HCV RNA. The levels of blood urea nitrogen and creatinine were 61 and 9.01 mg/dl, respectively. His model for end-stage liver disease score was 22. A computed tomography scan revealed the presence of liver cirrhosis, splenomegaly and developed collateral vessels such as splenorenal shunt, recanalized paraumbilical vein and gastric varices. No definite hepatocellular carcinomas were detected (fig. [1a](#F1){ref-type="fig"}). The bilateral kidneys were very atrophic, which was consistent with irreversible renal failure (fig. [1b](#F1){ref-type="fig"}). In summary, he had decompensated hepatitis C cirrhosis without serum HCV RNA. He had non-diabetic renal failure after 3 years on hemodialysis. He showed good general function except for the liver and kidney failure. Therefore, the patient was expected to have a good prognosis after LDLT.

The donor was his healthy 58-year-old wife with identical blood type to the recipient. The right lobe graft was procured using a typical method described elsewhere \[[@B1], [@B11], [@B12], [@B13], [@B14]\]. The actual graft weight was 546 g, which accounted for 50.4% of the recipient\'s standard liver volume.

In the recipient, intraoperative continuous hemodiafiltration (CHDF) without water removal was started immediately via the right femoral vein after laparotomy. The CHDF provided a stable acid-base and electrolyte balance. A total hepatectomy and implantation were performed under stable hemodynamics using an extracorporeal veno-venous bypass. The V5, right inferior hepatic vein and right hepatic vein of the right lobe graft were reconstructed to have a co-orifice using the left internal jugular vein and explanted portal vein grafts of the recipient at the backtable according to our usual method \[[@B15], [@B16]\]. Operative time was 14 h 22 min. The anhepatic, cold ischemic and warm ischemic times were 140, 169 and 65 min, respectively. The blood loss was 2,000 g, for which 10 units of red cell concentrate, 10 units of fresh-frozen plasma and 30 units of platelet concentrate were transfused.

The postoperative courses of the recipient and the donor were uneventful. CHDF was continued until postoperative day 4, at which point CHDF was converted to hemodialysis. The amount of water removal was appropriately adjusted according to blood pressure, central venous pressure and body weight. The drained ascites was below 500 ml/day and all abdominal drains were removed by postoperative day 6 except for the biliary stents (table [1](#T1){ref-type="table"}). Other than the renal replacement therapy and dose modulation of renal excretory drugs such as acyclovir, the perioperative management of the recipient was typical, as previously described \[[@B1], [@B11], [@B12], [@B13], [@B14]\]. Immunosuppression was induced with intravenous methylprednisolone and then switched to oral prednisolone, cyclosporin A and mycophenolate mofetil. He left the intensive care unit on postoperative day 5 and was discharged on postoperative day 36 with good hepatic function.

Discussion {#sec1_3}
==========

To the best of our knowledge, this is the first report of LDLT for a patient on chronic hemodialysis. Deceased donor LKT is a standard therapy for ELKD \[[@B4], [@B5]\]. The posttransplant 2-year survival rates are 75.9% for deceased donor LKT and 70.8% for deceased donor isolated liver transplantation for ELKD on hemodialysis \[[@B5]\]. On the other hand, living donor LKT is invasive for the donor and is not established. An alternative strategy is LDLT and continuation of hemodialysis. However, LDLT for a patient on hemodialysis is potentially risky, and most surgeons hesitate to perform the procedure. In fact, LDLT for a patient on hemodialysis has never been reported, and thus the indications are unknown.

In the present case, there were three indications for LDLT. First, the patient was seronegative for HCV RNA. Undetectable serum HCV RNA before liver transplantation has been shown to decrease the rate of posttransplant disease recurrence \[[@B17], [@B18]\]. Nudo et al. \[[@B18]\] reported that patients with sustained viral response for interferon therapy, as determined by a sensitive assay (lower limit \<600 IU/ml), had no virological recurrence, histological recurrence or graft failure. The present patient was determined to be seronegative for HCV RNA by an even more sensitive assay (lower limit \<15 IU/ml). Therefore, he was expected to have a good prognosis without hepatitis C recurrence after LDLT. Second, the etiology for the renal failure was non-diabetic. Non-diabetic patients on hemodialysis show much better survival rates than diabetic patients on hemodialysis \[[@B19]\]. Third, the patient had only been on hemodialysis for 3 years and had no other complications. He had good general functions including cardiac and pulmonary functions. Taking these three factors into consideration, LDLT was indicated for this patient.

Simultaneous or sequential LKT from the donor was not indicated for two reasons. First, liver-kidney donation from a single donor has not been established and is very invasive, especially for the relatively old donor in this case (58 years of age). Second, the recipient was expected to continue hemodialysis because he had only been on hemodialysis for 3 years.

The intraoperative and postoperative points were use of CHDF, care of in-out balance and drug dose modulation. CHDF was very useful as a peritransplant renal replacement therapy with stable hemodynamics. The other managements did not need to be specialized.

In conclusion, to the best of our knowledge, this is the first report of LDLT for a patient on chronic hemodialysis. Being on hemodialysis is no contraindication for LDLT. Isolated LDLT is a feasible option for a patient with ELKD on hemodialysis.

Disclosure Statement {#sec1_4}
====================

The authors have no conflict of interest.

![Pretransplant computed tomography scan. **a** The liver was cirrhotic and had no definite hepatocellular carcinomas. Moderate ascites, recanalized paraumbilical vein (arrow), gastric varices (arrowhead) and splenomegaly were identified. **b** The bilateral kidneys were very atrophic (arrows).](crg-0007-0299-g01){#F1}
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Posttransplant course

  POD   Renal replacement/water removal, ml   Ascites, ml   Body weight, kg
  ----- ------------------------------------- ------------- -----------------
  1     CHDF/420                              385           54.1
  2     CHDF/1,290                            122           54.5
  3     CHDF/1,010                            278           54.1
  4     HD/2,000                              191           53.1
  5     none                                  065           52.5
  6     none                                  none          53.6
  7     HD/1,800                              none          52.8

POD = Postoperative day; HD = hemodialysis.
